Evidence map›Paper›PMID 39904979›Full record

ArticleNature communications2025

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.

Julia Velz, Lena K Freudenmann, Gioele Medici, Marissa Dubbelaar, Malte Mohme, David R Ghasemi, Jonas Scheid, Daniel J Kowalewski, Angelica B Patterson, Anna M Zeitlberger and 27 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Review
  2. Article
  3. Review
  4. Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Julia Velz *Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-8027-9918
Lena K Freudenmann *Institute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-9827-4979
Gioele Medici *Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2279-6014
Marissa DubbelaarDepartment of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-4930-1467
Malte MohmeDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0003-0627-9092
David R GhasemiDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3844-9933
Jonas ScheidInstitute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5923-1343
Daniel J KowalewskiInstitute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-0482-9927
Angelica B PattersonInstitute of Immunobiology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland.
Anna M ZeitlbergerDepartment of Neurosurgery, Cantonal Hospital St.Gallen, St.Gallen, Switzerland.
Katrin LamszusDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Manfred WestphalDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Matthias EyrichDepartment of Pediatric Haematology, Oncology and Stem Cell Transplantation, University Children's Hospital, University Medical Center, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-8099-5903
Martina Messing-JüngerDepartment of Neurosurgery, Asklepios Children's Hospital, Sankt Augustin, Germany.
Andreas RöhrigDepartment of Neurosurgery, Asklepios Children's Hospital, Sankt Augustin, Germany.
Harald ReinhardDepartment of Pediatrics, Asklepios Children's Hospital, Sankt Augustin, Germany.
Kévin BeccariaDepartment of Pediatric Neurosurgery, Necker Enfants Malades Hospital, APHP, Université Paris Cite, Paris, France.
Rogeiro B CraveiroDepartment of Orthodontic, Dental Clinic, University Hospital of RWTH Aachen, Aachen, Germany.
Beat M FreyBlood Transfusion Service, Swiss Red Cross, Schlieren, Switzerland.ORCID http://orcid.org/0000-0002-2514-8621
Martin SillDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7616-7665
Sven NahnsenQuantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-4375-0691
Marie GauderQuantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0001-8329-6924
Konstantina KapolouLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Manuela SilginerLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Tobias WeissLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5533-9429
Hans-Georg WirschingLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-6254-4204
Patrick RothLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Michael GrotzerDepartment of Oncology, University Children's Hospital Zürich, Zürich, Switzerland.
Niklaus KrayenbühlDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-1089-221X
Oliver BozinovDepartment of Neurosurgery, Cantonal Hospital St.Gallen, St.Gallen, Switzerland.
Luca RegliDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4639-4474
Hans-Georg RammenseeInstitute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-1614-2647
Elisabeth J RushingDepartment of Neuropathology, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-7616-6320
Felix SahmDepartment of Neuropathology, Heidelberg University Hospital, and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5441-1962
Juliane S WalzGerman Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0001-6404-7391
Michael WellerLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-1748-174X
Marian C NeidertLaboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. marian.neidert@kssg.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T cell antigens in medulloblastoma. We map the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and perform comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma is shown to be a rich source of tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins are subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) is rare. Functional testing of top-ranking novel candidate antigens demonstrates the induction of peptide-specific T cell responses, supporting their potential for T cell immunotherapy. This study is an in-depth mapping of naturally presented T cell antigens in medulloblastoma. Integration of immunopeptidomics, transcriptomics, and epigenetic data leads to the identification of a large set of actionable targets that can be further used for the translation into the clinical setting by facilitating the informed design of immunotherapeutic approaches to children with medulloblastoma.

Indexed as

Antigens, NeoplasmCerebellar NeoplasmsMedulloblastomaT-LymphocytesAntigen PresentationChildChild, PreschoolFemaleHistocompatibility Antigens Class IHLA AntigensHumansMaleMultiomicsPeptidesProteomicsAntigens, NeoplasmHistocompatibility Antigens Class IHLA AntigensPeptides

Identifiers

PMID39904979
PMCPMC11794601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.